Shares of Verrica Pharmaceuticals Inc (NASDAQ:VRCA) have been assigned an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating.

Brokerages have set a 12-month consensus price objective of $28.33 for the company and are anticipating that the company will post ($0.25) EPS for the current quarter, according to Zacks. Zacks has also assigned Verrica Pharmaceuticals an industry rank of 105 out of 255 based on the ratings given to related companies.

VRCA has been the topic of several recent analyst reports. Bank of America initiated coverage on Verrica Pharmaceuticals in a research report on Tuesday, July 10th. They issued a “buy” rating and a $26.00 price target on the stock. Cowen initiated coverage on Verrica Pharmaceuticals in a research report on Tuesday, July 10th. They issued an “outperform” rating and a $35.00 price target on the stock. Jefferies Financial Group initiated coverage on Verrica Pharmaceuticals in a research report on Tuesday, July 10th. They issued a “buy” rating and a $24.00 price target on the stock. Finally, Zacks Investment Research downgraded Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, September 12th.

NASDAQ VRCA traded up $0.09 during trading on Thursday, hitting $16.45. The company’s stock had a trading volume of 7,930 shares, compared to its average volume of 71,269. Verrica Pharmaceuticals has a 52 week low of $13.23 and a 52 week high of $23.29.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings results on Tuesday, August 7th. The company reported ($1.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.76). research analysts forecast that Verrica Pharmaceuticals will post -1.15 earnings per share for the current fiscal year.

In other news, Director Paul B. Manning acquired 33,000 shares of the stock in a transaction dated Friday, August 10th. The shares were acquired at an average cost of $15.08 per share, for a total transaction of $497,640.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ted White acquired 2,505 shares of the stock in a transaction dated Wednesday, August 15th. The shares were purchased at an average price of $15.69 per share, for a total transaction of $39,303.45. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 35,805 shares of company stock worth $541,851.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Capital Investment Advisory Services LLC bought a new stake in shares of Verrica Pharmaceuticals during the second quarter valued at approximately $211,000. Laurion Capital Management LP bought a new stake in shares of Verrica Pharmaceuticals during the second quarter valued at approximately $395,000. Dean Capital Investments Management LLC bought a new stake in shares of Verrica Pharmaceuticals during the second quarter valued at approximately $676,000. Asymmetry Capital Management L.P. bought a new stake in shares of Verrica Pharmaceuticals during the second quarter valued at approximately $1,184,000. Finally, Kornitzer Capital Management Inc. KS bought a new stake in shares of Verrica Pharmaceuticals during the second quarter valued at approximately $2,905,000. Institutional investors and hedge funds own 31.86% of the company’s stock.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals, Inc operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris.

Further Reading: Market Capitalization and Individual Investors

Get a free copy of the Zacks research report on Verrica Pharmaceuticals (VRCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.